T-cell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Pedroza Gonzalez, Alexander ^a   Kwekkeboom, Jaap ^a   Sprengers, Dave ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal cancer; GITRL; Hepatocellular carcinoma; Immunotherapy; Liver cancer; Liver metastasis; Regulatory T cells; T cells

Indexed keywords

CD4 ANTIGEN; DENDRITIC CELL VACCINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INDUCIBLE T CELL COSTIMULATOR; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ABLATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL EFFECTIVENESS; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886943951     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22450     Document Type: Article

References (10)

1. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27:147-63; PMID:19302037; http://dx.doi.org/10.1146/annurev.immunol. 021908.132629.
2. Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol 2010; 22:364-73; PMID:20520544; http://dx.doi.org/10.1097/CCO.0b013e32833a6c8a.
3. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012; 1:48-55; PMID:22720211; http://dx.doi.org/10.4161/ onci.1.1.18344.
4. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258.
5. Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011; 208:479-90; PMID:21339324; http://dx.doi.org/10.1084/ jem.20102131.
6. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093.
7. Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2012; In Press; PMID:22911397; http://dx.doi.org/10.1002/ hep.26013.
8. Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, Goutagny N, et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res 2011; 71:6143-52; PMID:21852386; http://dx.doi. org/10.1158/0008-5472.CAN-11-0573
9. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki- Eldin A, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011; 6:e24671; PMID:21935436; http:// dx.doi.org/10.1371/journal.pone.0024671.
10. Nocentini G, Riccardi C. GITR: a modulator of immune response and inflammation. Adv Exp Med Biol 2009; 647:156-73; PMID:19760073; http:// dx.doi.org/10.1007/978-0-387-89520-8_11.